1. Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.
- Author
-
Xuan Y, Ding TT, Mao XL, Pang S, He R, Qin L, and Yuan JZ
- Subjects
- Animals, Male, Mice, Kidney pathology, Kidney drug effects, Kidney metabolism, Disease Models, Animal, Hypoglycemic Agents pharmacology, Hypoglycemic Agents therapeutic use, Liraglutide pharmacology, Liraglutide therapeutic use, Diet, High-Fat adverse effects, AMP-Activated Protein Kinases metabolism, Mice, Inbred C57BL, Calcium-Calmodulin-Dependent Protein Kinase Kinase metabolism, Signal Transduction drug effects, Obesity complications, Obesity drug therapy
- Abstract
Objective: Liraglutide, a glucagon-like peptide-1 receptor agonist, has been shown to regulate blood sugar and control body weight, but its ability to treat obesity-related nephropathy has been poorly studied. Therefore, this study was designed to observe the characteristics and potential mechanism of liraglutide against obesity-related kidney disease., Methods: Thirty-six C57BL/6J male mice were randomly divided into six groups ( n = 6 per group). Obesity-related nephropathy was induced in mice by continuous feeding of high-fat diet (HFD) for 12 weeks. After 12 weeks, liraglutide (0.6 mg/kg) and AMP-activated protein kinase (AMPK) agonists bortezomib (200 μg/kg) were injected for 12 weeks, respectively. Enzyme-linked immunosorbent assay was employed to detect the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, blood urea nitrogen, creatinine in serum, as well as urinary protein in urine. Besides, hematoxylin-eosin staining and periodic acid-Schiff staining were used to observe the pathological changes of kidney tissue; immunohistochemistry, western blot, and real-time quantitative PCR to assess the calmodulin-dependent protein kinase kinase beta (CaMKKβ)/AMPK signaling pathway activation., Results: Liraglutide significantly reduced serum lipid loading, improved kidney function, and relieved kidney histopathological damage and glycogen deposition in the mouse model of obesity-related kidney disease induced by HFD. In addition, liraglutide also significantly inhibited the CaMKKβ/AMPK signaling pathway in kidney tissue of HFD-induced mice. However, bortezomib partially reversed the therapeutic effect of liraglutide on HDF-induced nephropathy in mice., Conclusions: Liraglutide has a therapeutic effect on obesity-related kidney disease, and such an effect may be achieved by inhibiting the CaMKKβ/AMPK signaling pathway in kidney tissue.
- Published
- 2024
- Full Text
- View/download PDF